{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-004884","form_type":"8-K","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.603460+00:00","generated_at":"2026-05-27T22:02:17.181493+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"ReShape Lifesciences amends convertible note, extends maturity to April 2025","bullets":["Maturity extended to earlier of Vyome Therapeutics merger close or 90 days after Jan 14, 2025 (April 16, 2025).","Mandatory prepayment of subsequent financing proceeds reduced from 66% to 50%.","Investor not required to convert the note at merger closing; $45,000 cash extension fee payable at maturity.","Amendment executed with Ascent Partners Fund LLC on $833,333.34 senior secured convertible note."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-004884","json":"https://secwatch.observer/filing/0001104659-25-004884.json","markdown":"https://secwatch.observer/filing/0001104659-25-004884.md","text":"https://secwatch.observer/filing/0001104659-25-004884.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000110465925004884/0001104659-25-004884-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000110465925004884/tm253570d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T22:02:17.181493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}